Key result
A new generation of risk-free, affordable, and globally scalable inactivated poliovirus vaccines is urgently needed to maintain universal immunity in the post-eradication era.
Highlights the urgent need for a new generation of risk-free, affordable, and globally scalable polio vaccines for the post-eradication era.
Answers are grounded in this paper and cite their sources.
Urges R&D investment in novel IPV now; leaves open optimal platforms meeting all post-eradication criteria.
Twenty years of global polio eradication efforts may soon eliminate the transmission of wild-type poliovirus. However, new information that has been learned about poliovirus, as well as the political realities of a modern world, demand that universal immunity against poliomyelitis be maintained, even after wild-type poliovirus is eradicated. Although 2 excellent vaccines have proven to be highly effective in the past, neither the live-attenuated vaccine nor the currently used inactivated vaccine are optimal for use in the posteradication era. Therefore, concerted efforts are urgently needed to develop a new generation of vaccine that is risk-free and affordable and can be produced on a global scale. Here, we discuss the desired properties of a vaccine and methods to create a new polio vaccine.
No takes yet. Share an insight, caveat, or question.
Chumakov et al. (2008) conducted a review in Poliomyelitis. New generation of inactivated poliovirus vaccines was evaluated. A new generation of risk-free, affordable, and globally scalable inactivated poliovirus vaccines is urgently needed to maintain universal immunity in the post-eradication era.
Synapse has enriched 10 related papers. Consider them for comparative context: